By vgreene, 5 June, 2020 Study considerations: randomized, but open label; early termination due to epidemic containment; small sample size, possibly underpowered; median time 30 days btwn sx onset and randomization; SOC not protocolized, study center variability; limited f/u
By vgreene, 5 June, 2020 No significant difference in time to clinical improvement w/in 28 days overall (convalescent plasma 51.9%, control 43.1%); in pts w/ severe dz, time to clinical improvement rate higher w/ convalescent plasma (91.3%) vs control (68.2%); no significant diff
By vgreene, 5 June, 2020 Donors recovered from COVID-19, discharged from hospital >14 days, S-protein-specific Ab titers >1:640
By vgreene, 5 June, 2020 Multicenter, open-label, randomized study; 103 hospitalized pts (median age 70y) w/ confirmed severe or life-threatening COVID-19, randomized 1:1 by dz severity to receive convalescent plasma 200 mL (n=52) or SOC alone (n=51)
By vgreene, 5 June, 2020 A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid 19
By vgreene, 5 June, 2020 Study considerations: recruitment through social and traditional media platforms w/ enrollment via internet-based survey; f/u via email surveys, 10% didn’t complete day 14 survey; access to testing limited; sample-size adjusted mid-study; delay btwn SARS-
By vgreene, 5 June, 2020 No difference in lab-confirmed COVID-19 incidence or COVID-19 illness w/in 14 days (HCQ 11.8%, placebo 14.3%); 1 hospitalization per group, no deaths or arrhythmias; ADRs more common w/ HCQ
By vgreene, 5 June, 2020 Double-blinded RCT; 821 asymptomatic pts (median age 40y) w/ mod-high COVID-19 exposure risk (66.4% HCWs, 29.8% household contacts, 3.8% other occupations) given HCQ 800 mg PO x1, then 600 mg 6-8h later, then 600 mg PO daily x4 days (n=414) or placebo (n=